AbbVie's $10.9B Apogee Buy Targets Dupixent; 1st Solid Tumor CAR-T Approved in China

AbbVie drops ten point nine billion dollars on Apogee Therapeutics — its biggest acquisition since Allergan — and both stocks rally.

Meanwhile, the first CAR-T ever approved for a solid tumor just cleared in China, and HHS is overhauling clinical trial rules with Beijing in the crosshairs. Monday is loaded.

Welcome to The Pharma Closeout for Monday, June twenty-second, twenty twenty-six. I'm Alex Mercer.

And I'm Maya Patel. Let's get to it.

Our top story. AbbVie announced it's acquiring Apogee Therapeutics for approximately ten point nine billion dollars — the year's second-largest biotech buyout and AbbVie's biggest deal since the sixty-three billion dollar Allergan takeover in twenty nineteen. Apogee stock jumped forty-six point six six percent on the announcement. AbbVie — the acquirer — climbed six point two five percent to close at two hundred thirty dollars and one cent. When both sides of a deal this large rally on the same day, the market is telling you something.

An acquirer moving up more than six percent on a deal this size means Wall Street thinks the buyer got a bargain. What AbbVie's landing is a pipeline of long-acting autoimmune drugs that its own management described as having mega-blockbuster sales potential — headlined by a Dupixent competitor going after a franchise generating north of thirteen billion annually for Regeneron and Sanofi.

Continuity note for regular listeners. We flagged Apogee back in March when zumilokibart dose-optimization data from three hundred forty-seven patients was expected this quarter. AbbVie apparently didn't want to wait for the readout — they bought the entire company. Let's bring in Marcus Webb for the deal structure.

The long-acting formulation is what lifts this beyond a me-too thesis. If the dosing convenience holds — quarterly or even less frequent administration in atopic derm and asthma — the competitive axis shifts from efficacy to adherence. And real-world payer conversations increasingly hinge on adherence-adjusted outcomes, not pivotal trial response rates.

Which puts Regeneron's pricing power directly in the crosshairs. They've spent years extending Dupixent through label expansions and deeper penetration — building what looked like an unassailable market position. Now AbbVie, with arguably the strongest immunology commercial engine in the industry, is aiming squarely at that revenue base.

If AbbVie can convert pipeline to registrational data fast enough. These are early-to-mid-stage assets, not a commercial product. The development clock starts now, and Regeneron has a multi-year head start in both market penetration and real-world evidence generation. That's a head start measured in years of formulary positioning, not months.

Fair. But even the pipeline overhang shifts the negotiation. Payers start referencing credible late-stage competition well before any drug reaches the market. The moment AbbVie posts Phase 3 enrollment targets and a timeline, Regeneron faces a fundamentally different payer dynamic than the one they've enjoyed.

Which is exactly why the question isn't just clinical — it's about clock speed. Does Regeneron respond with next-generation formulations before AbbVie reaches registration? Either way, the monopoly pricing window on IL-four, IL-thirteen just shortened. Anyone modeling Dupixent revenue past twenty-thirty should be revising assumptions this week.

That repricing exercise extends well beyond Dupixent. Shifting to the deal roundup — Merck's IBD drug, the asset it acquired through the ten point eight billion dollar Prometheus Biosciences deal, just claimed its first Phase 3 win. Merck closed up one point four one percent at a hundred fifteen forty-eight. This validates the precision medicine approach Prometheus was built on and gives Merck a registrational-stage asset well outside its core oncology franchise. The Street has been waiting for exactly this kind of pipeline validation.

Merck needs assets that counter the Keytruda LOE narrative, and registrational IBD data does exactly that. It's not just Merck — cAMPfield launching with a hundred eighty million for a different IBD asset in the same cycle tells you the market sees real opportunity in precision IBD therapeutics. One Phase 3 win doesn't replace Keytruda, but the diversification story just became investable.

Elsewhere, Kardigan raised four hundred million in its IPO — the fourth biotech this year to hit that threshold and the most in a single year since twenty twenty-one, per BioPharma Dive data. KARD up three and a half percent. Two startup launches worth flagging: Bionyra debuted with a hundred sixty-five million dollar Series A for next-gen immune drugs, founded by a Sanofi alum bringing I&I candidates sourced from China. And MacroGenics popped ten point nine percent on a milestone payment from Sanofi tied to the TZIELD approval. Two I&I startups, a four-hundred-million-dollar heart drug IPO, and a milestone payout — all in one session. The immunology funding window is wide open, and the AbbVie headline is only going to widen it.

On the regulatory side, the headline today is genuinely historic. CARsgen Biosciences received Chinese approval for its Claudin eighteen point two-targeted CAR-T therapy in gastric cancer. Per FiercePharma, this is the first CAR-T approved anywhere in the world for a solid tumor.

That rewrites the playbook for the entire cell therapy field. Every solid tumor CAR-T program in development just gained a regulatory precedent to point to.

Pump the brakes before extrapolating. Gastric cancer was always going to be the beachhead because Claudin eighteen point two offers the surface density and expression homogeneity you need for reliable T-cell engagement in a meaningful subset of these patients. That's a target biology story, not a manufacturing story. Pancreatic adenocarcinoma, GBM — where antigen heterogeneity and the stromal barrier are fundamentally different problems — that's a much longer road. This approval opens the door, but the corridor beyond gastric is long and narrow.

And the geopolitical overlay makes this even more charged.

That's the collision that matters most. This milestone lands in China on the same morning HHS rolls out sweeping clinical trial reforms — reforms RFK Junior explicitly framed as measures to counter China's biotech influence. Layer on Treasury reportedly assessing options to screen U.S. investments in Chinese biotech, WuXi Biologics resetting the timeline on its Massachusetts factory, and the picture is clear — cross-border biotech policy is tightening on multiple fronts simultaneously. For anyone at Novartis, BMS, or Legend with solid tumor CAR-T ambitions, you're now chasing a benchmark rather than racing toward an unclaimed first.

Different arena, same competitive instinct. Alnylam received a regulatory reprimand over promotional activity — and the complaint came from Pfizer.

When a competitor files the complaint rather than a routine inspection triggering the action, that's commercial warfare through the regulatory channel. The question now is whether other companies start deploying the same tactic wherever therapeutic areas overlap — because that fundamentally reshapes how you model competitive risk.

Looking ahead. The Moderna mFlusiva PDUFA on August fifth remains the big vaccine catalyst on the calendar, even as Moderna shares dropped seven point two two percent today despite the recent unanimous VRBPAC vote. Causation is unclear, but that disconnect between panel support and stock direction deserves monitoring. Separately, the Novo Nordisk ransomware situation continues to develop — hackers now claim drug formulations and AI models are for sale after a twenty-five million dollar ransom was rejected. That's an IP security story with implications well beyond one company. Also worth noting — UniQure is now planning to file AMT-one-thirty for approval after the FDA reversed course on a prior rejection, another signal of the regulatory posture shift since the leadership changes. And watch how CROs and CDMOs with China exposure respond to the HHS reforms — strategic repositioning announcements could come within days.

We've previously flagged Novartis's pelacarsen cardiovascular outcome data as expected before the end of this month. We're inside two weeks of that window. If those results reshape the Lp(a) reduction thesis the way the field expects, it resets the entire cardiovascular risk-reduction conversation heading into the second half. Clear your calendar.

That's your Pharma Closeout for Monday, June twenty-second. AbbVie stakes ten point nine billion on the post-Dupixent era, CARsgen's solid tumor CAR-T rewrites the cell therapy map, Merck's Prometheus bet starts paying dividends — and Pfizer just turned the regulatory complaint process into a competitive weapon. If this briefing saves you time, follow us on Spotify, Apple Podcasts, or wherever you listen and drop us a rating — it helps more people find the show. We'll be back tomorrow.

Big Monday. Enjoy your evening, everyone. See you tomorrow. ### Episode Metadata **Title:** AbbVie's $10.9B Apogee Buy Targets Dupixent; First Solid Tumor CAR-T Approved in China; Merck IBD Phase 3 Win | Jun 22, 2026 **Description:** AbbVie bets $10.9B on Apogee Therapeutics to challenge Dupixent — its biggest deal since Allergan. Plus: the first CAR-T approved for a solid tumor clears in China, Merck's $10.8B Prometheus IBD bet pays off with a Phase 3 win, and HHS clinical trial reforms target China. **Tags:** AbbVie, Apogee Therapeutics, zumilokibart, Dupixent, Regeneron, Sanofi, CARsgen, CAR-T, Claudin 18.2, solid tumor, gastric cancer, Merck, Prometheus Biosciences, IBD, Keytruda, HHS, RFK Jr, clinical trial reform, Moderna, mFlusiva, Alnylam, Pfizer, Kardigan, MacroGenics, TZIELD, Bionyra, cAMPfield, WuXi Biologics, Novartis, pelacarsen, UniQure, AMT-130, Novo Nordisk, ransomware, pharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals #